| # | Title | Journal | Year | Citations |
|---|
| 1 | Age‐related behavioral changes from young to old age in male mice of a C57BL/6J strain maintained under a genetic stability program | Neuropsychopharmacology Reports | 2019 | 119 |
| 2 | Post‐COVID‐19 fatigue and anhedonia: A cross‐sectional study and their correlation to post‐recovery period | Neuropsychopharmacology Reports | 2021 | 72 |
| 3 | Hippocampal subregion abnormalities in schizophrenia: A systematic review of structural and physiological imaging studies | Neuropsychopharmacology Reports | 2018 | 58 |
| 4 | Comprehensive behavioral analysis of heterozygous Syngap1 knockout mice | Neuropsychopharmacology Reports | 2019 | 58 |
| 5 | Eye movement characteristics in schizophrenia: A recent update with clinical implications | Neuropsychopharmacology Reports | 2020 | 57 |
| 6 | Anxiety and Depression in Health Workers and General Population During COVID‐19 in IRAN: A Cross‐Sectional Study | Neuropsychopharmacology Reports | 2021 | 52 |
| 7 | Neuropharmacology of Antiseizure Drugs | Neuropsychopharmacology Reports | 2021 | 49 |
| 8 | Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia” | Neuropsychopharmacology Reports | 2021 | 48 |
| 9 | Differential effects of stress exposure via two types of restraint apparatuses on behavior and plasma corticosterone level in inbred male BALB/cAJcl mice | Neuropsychopharmacology Reports | 2020 | 40 |
| 10 | Anticraving therapy for alcohol use disorder: A clinical review | Neuropsychopharmacology Reports | 2018 | 39 |
| 11 | An initial analysis of the UK Medical Cannabis Registry: Outcomes analysis of first 129 patients | Neuropsychopharmacology Reports | 2021 | 33 |
| 12 | Bee honey protects astrocytes against oxidative stress: A preliminary in vitro investigation | Neuropsychopharmacology Reports | 2019 | 32 |
| 13 | Prescription patterns in patients with schizophrenia in Japan: First‐quality indicator data from the survey of “Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)” project | Neuropsychopharmacology Reports | 2020 | 32 |
| 14 | Prefrontal cortex infusion of beta‐hydroxybutyrate, an endogenous NLRP3 inflammasome inhibitor, produces antidepressant‐like effects in a rodent model of depression | Neuropsychopharmacology Reports | 2020 | 31 |
| 15 | Raising awareness of suicide prevention during the COVID‐19 pandemic | Neuropsychopharmacology Reports | 2020 | 30 |
| 16 | Microglia attenuate the kainic acid‐induced death of hippocampal neurons in slice cultures | Neuropsychopharmacology Reports | 2020 | 25 |
| 17 | Effects of chronic fentanyl administration on behavioral characteristics of mice | Neuropsychopharmacology Reports | 2019 | 23 |
| 18 | Hypothalamic‐pituitary‐adrenal axis differentially responses to morning and evening psychological stress in healthy subjects | Neuropsychopharmacology Reports | 2019 | 23 |
| 19 | Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole | Neuropsychopharmacology Reports | 2021 | 23 |
| 20 | Gut permeability and its clinical relevance in schizophrenia | Neuropsychopharmacology Reports | 2022 | 23 |
| 21 | Transcriptomic evidence for immaturity induced by antidepressant fluoxetine in the hippocampus and prefrontal cortex | Neuropsychopharmacology Reports | 2019 | 22 |
| 22 | A randomized controlled study of the effect of ifenprodil on alcohol use in patients with alcohol dependence | Neuropsychopharmacology Reports | 2018 | 21 |
| 23 | Risk factors for pneumonia in patients with schizophrenia | Neuropsychopharmacology Reports | 2018 | 21 |
| 24 | Application of eye trackers for understanding mental disorders: Cases for schizophrenia and autism spectrum disorder | Neuropsychopharmacology Reports | 2019 | 21 |
| 25 | Dietary heat‐killed Lactobacillus brevis SBC8803 (SBL88™) improves hippocampus‐dependent memory performance and adult hippocampal neurogenesis | Neuropsychopharmacology Reports | 2019 | 20 |
| 26 | Prevalence of corona‐associated anxiety and mental health disorder among dentists during the COVID‐19 pandemic | Neuropsychopharmacology Reports | 2021 | 20 |
| 27 | Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats | Neuropsychopharmacology Reports | 2019 | 19 |
| 28 | PET technology for drug development in psychiatry | Neuropsychopharmacology Reports | 2020 | 19 |
| 29 | Care difficulties and burden during COVID‐19 pandemic lockdowns among caregivers of people with schizophrenia: A cross‐sectional study | Neuropsychopharmacology Reports | 2021 | 19 |
| 30 | Comprehensive behavioral analysis of tryptophan 2,3‐dioxygenase (Tdo2) knockout mice | Neuropsychopharmacology Reports | 2018 | 18 |
| 31 | SSRIs: Applications in inflammatory lung disease and implications for COVID‐19 | Neuropsychopharmacology Reports | 2021 | 18 |
| 32 | Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment‐resistant depression | Neuropsychopharmacology Reports | 2021 | 17 |
| 33 | Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study | Neuropsychopharmacology Reports | 2021 | 17 |
| 34 | Dietary intake of glucoraphanin during pregnancy and lactation prevents the behavioral abnormalities in the offspring after maternal immune activation | Neuropsychopharmacology Reports | 2020 | 16 |
| 35 | Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment‐resistant major depressive disorder | Neuropsychopharmacology Reports | 2020 | 16 |
| 36 | Evaluation of the usefulness of saliva for DNA methylation analysis in cohort studies | Neuropsychopharmacology Reports | 2019 | 15 |
| 37 | Open source code for behavior analysis in rodents | Neuropsychopharmacology Reports | 2019 | 15 |
| 38 | Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8‐week, double‐blind, multicenter, randomized controlled study | Neuropsychopharmacology Reports | 2019 | 15 |
| 39 | Plasma levels of matrix metalloproteinase‐9 (MMP‐9) are associated with cognitive performance in patients with schizophrenia | Neuropsychopharmacology Reports | 2020 | 15 |
| 40 | Examination of the influence of cedar fragrance on cognitive function and behavioral and psychological symptoms of dementia in Alzheimer type dementia | Neuropsychopharmacology Reports | 2020 | 14 |
| 41 | Evidence‐based insomnia treatment strategy using novel orexin antagonists: A review | Neuropsychopharmacology Reports | 2021 | 14 |
| 42 | Association between the examination rate of treatment‐resistant schizophrenia and the clozapine prescription rate in a nationwide dissemination and implementation study | Neuropsychopharmacology Reports | 2022 | 14 |
| 43 | Intracerebroventricular administration of oxytocin and intranasal administration of the oxytocin derivative improve β‐amyloid peptide (25–35)‐induced memory impairment in mice | Neuropsychopharmacology Reports | 2022 | 14 |
| 44 | A pharmacogenetics approach to pain management | Neuropsychopharmacology Reports | 2018 | 13 |
| 45 | Recent findings on subjective well‐being and physical, psychiatric, and social comorbidities in individuals with schizophrenia: A literature review | Neuropsychopharmacology Reports | 2022 | 13 |
| 46 | Characteristics of facial muscle activity during voluntary facial expressions: Imaging analysis of facial expressions based on myogenic potential data | Neuropsychopharmacology Reports | 2019 | 12 |
| 47 | Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double‐blind, placebo‐controlled trial | Neuropsychopharmacology Reports | 2019 | 12 |
| 48 | Decreased serum levels of thrombospondin‐1 in female depressed patients | Neuropsychopharmacology Reports | 2020 | 12 |
| 49 | Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study | Neuropsychopharmacology Reports | 2020 | 12 |
| 50 | Decreased bone mineral density in ovariectomized mice is ameliorated after subsequent repeated intermittent administration of (R)‐ketamine, but not (S)‐ketamine | Neuropsychopharmacology Reports | 2020 | 12 |
